Showing results (141-150 of 158) with videos related to

Sort By:
Pageof 16
Journal of Gastrointestinal Oncology|November 17, 2022
A signature of Prevotella copri and Faecalibacterium prausnitzii depletion, and a link with bacterial glutamate degradation in the Kenyan colorectal cancer patientsSarah Obuya, Amr Elkholy, Nagavardhini Avuthu, et al.
NPJ Breast Cancer|August 8, 2025
Race-related host and microbe transcriptomic signatures in triple-negative breast cancerRoshan Kumar, Susan Duyar-Ayerdi, Aishwarya Sundaresan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2024
Differential Responses to Immune Checkpoint Inhibitors are Governed by Diverse Mismatch Repair Gene AlterationsMoh'd M Khushman, Michael D Toboni, Joanne Xiu, et al.
International Journal of Molecular Sciences|August 29, 2024
Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and OutcomesAshish Manne, Ashwini Esnakula, Ankur Sheel, et al.
JCI Insight|July 19, 2022
ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitorsHasibur Rehman, Darshan S Chandrashekar, Chakravarthi Balabhadrapatruni, et al.
Cell Reports. Medicine|December 27, 2024
Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroquineGanji Purnachandra Nagaraju, Madhu Sudhana Saddala, Jeremy B Foote, et al.
Heliyon|July 24, 2023
Microbiome diversity in African American, European American, and Egyptian colorectal cancer patientsAmr Elkholy, Nagavardhini Avuthu, Mohammed Abdalla, et al.
EMBO Molecular Medicine|October 26, 2022
A high-resolution 3D atlas of the spectrum of tuberculous and COVID-19 lung lesionsGordon Wells, Joel N Glasgow, Kievershen Nargan, et al.
Biorxiv : the Preprint Server for Biology|October 17, 2024
ADT-1004: A First-in-Class, Orally Bioavailable Selective pan-RAS Inhibitor for Pancreatic Ductal AdenocarcinomaDhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, Sujith Sarvesh, et al.
Molecular Cancer|March 14, 2025
ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinomaDhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, Sujith Sarvesh, et al.
Pageof 16